Correlation Between Accton Technology and SynCore Biotechnology

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Accton Technology and SynCore Biotechnology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Accton Technology and SynCore Biotechnology into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Accton Technology Corp and SynCore Biotechnology Co, you can compare the effects of market volatilities on Accton Technology and SynCore Biotechnology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Accton Technology with a short position of SynCore Biotechnology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Accton Technology and SynCore Biotechnology.

Diversification Opportunities for Accton Technology and SynCore Biotechnology

-0.33
  Correlation Coefficient

Very good diversification

The 3 months correlation between Accton and SynCore is -0.33. Overlapping area represents the amount of risk that can be diversified away by holding Accton Technology Corp and SynCore Biotechnology Co in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on SynCore Biotechnology and Accton Technology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Accton Technology Corp are associated (or correlated) with SynCore Biotechnology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of SynCore Biotechnology has no effect on the direction of Accton Technology i.e., Accton Technology and SynCore Biotechnology go up and down completely randomly.

Pair Corralation between Accton Technology and SynCore Biotechnology

Assuming the 90 days trading horizon Accton Technology Corp is expected to under-perform the SynCore Biotechnology. In addition to that, Accton Technology is 1.92 times more volatile than SynCore Biotechnology Co. It trades about -0.08 of its total potential returns per unit of risk. SynCore Biotechnology Co is currently generating about 0.08 per unit of volatility. If you would invest  3,490  in SynCore Biotechnology Co on November 28, 2024 and sell it today you would earn a total of  65.00  from holding SynCore Biotechnology Co or generate 1.86% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Accton Technology Corp  vs.  SynCore Biotechnology Co

 Performance 
       Timeline  
Accton Technology Corp 

Risk-Adjusted Performance

Weak

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Accton Technology Corp are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal basic indicators, Accton Technology may actually be approaching a critical reversion point that can send shares even higher in March 2025.
SynCore Biotechnology 

Risk-Adjusted Performance

Weak

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in SynCore Biotechnology Co are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of fairly stable basic indicators, SynCore Biotechnology is not utilizing all of its potentials. The latest stock price fuss, may contribute to near-short-term losses for the sophisticated investors.

Accton Technology and SynCore Biotechnology Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Accton Technology and SynCore Biotechnology

The main advantage of trading using opposite Accton Technology and SynCore Biotechnology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Accton Technology position performs unexpectedly, SynCore Biotechnology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in SynCore Biotechnology will offset losses from the drop in SynCore Biotechnology's long position.
The idea behind Accton Technology Corp and SynCore Biotechnology Co pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Other Complementary Tools

Stocks Directory
Find actively traded stocks across global markets
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance